E-viri
Recenzirano
Odprti dostop
-
Guilhot, François; Guilhot, Joëlle; Chastang, Claude; Michallet, Mauricette; Guerci, Agnès; Harousseau, Jean-Luc; Maloisel, Frédéric; Bouabdallah, Réda; Guyotat, Denis; Cheron, Nathalie; Nicolini, Franck; Abgrall, Jean-François; Tanzer, Joseph; Navarro, Maurice; Bordessoule, Dominique; Morice, Patrick; Ifrah, Norbert; Rochant, Henri; Vilque, Jean-Pierre; Delain, Martine; Bauters, Francis
The New England journal of medicine, 07/1997, Letnik: 337, Številka: 4Journal Article
Chronic myelogenous leukemia has a poor outcome when treated with hydroxyurea or busulfan. These agents can control the disease, but they do not eliminate Philadelphia chromosome–positive stem cells from the bone marrow. Allogeneic bone marrow transplantation, considered to be the only curative treatment, prolongs survival in up to 70 percent of a small subgroup of young patients. 1 An antileukemic effect of interferon alfa has been demonstrated and cytogenetic responses (the reduction or elimination of Philadelphia chromosome–positive cells in the marrow) have been reported in patients with chronic myelogenous leukemia. 2 – 4 Three randomized clinical trials comparing interferon alfa with conventional chemotherapy . . .
